Tezspire
Oct 07, 2024
DUPIXENT Receives First-Ever Biologic Approval for COPD: Adds Another Jewel in its Crown
After more than ten years without significant therapeutic advancements in chronic obstructive pulmonary disease (COPD), patients with this progressive condition now have two new treatment options, with more likely to follow. Regeneron and Sanofi recently announced that the FDA has broadened the use of the highly...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
